Cargando…

CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease

OBJECTIVE: Alzheimer’s disease (AD) is the sixth leading cause of death, with an average survival estimated between 5 and 10 years after diagnosis. Despite recent advances in diagnostic criteria of AD, few studies have used biomarker-based diagnostics to determine the prognostic factors of AD. We in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boumenir, Adla, Cognat, Emmanuel, Sabia, Severine, Hourregue, Claire, Lilamand, Matthieu, Dugravot, Aline, Bouaziz-Amar, Elodie, Laplanche, Jean-Louis, Hugon, Jacques, Singh-Manoux, Archana, Paquet, Claire, Dumurgier, Julien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440001/ https://www.ncbi.nlm.nih.gov/pubmed/30922415 http://dx.doi.org/10.1186/s13195-019-0481-4

Ejemplares similares

Biomarker profiles of Alzheimer’s disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau
por: Lafirdeen, Aysha S. Mohamed, et al.
Publicado: (2019)

Association between ATN profiles and mortality in a clinical cohort of patients with cognitive disorders
por: Régy, Mélina, et al.
Publicado: (2023)

Cerebrospinal Fluid Alpha-Synuclein Improves the Differentiation between Dementia with Lewy Bodies and Alzheimer’s Disease in Clinical Practice
por: Lilamand, Matthieu, et al.
Publicado: (2022)

A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging
por: Dumurgier, Julien, et al.
Publicado: (2022)

CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease
por: Mouton-Liger, François, et al.
Publicado: (2020)

Plasma neuregulin 1 as a synaptic biomarker in Alzheimer’s disease: a discovery cohort study
por: Vrillon, Agathe, et al.
Publicado: (2022)

Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study
por: Saddiki, Hana, et al.
Publicado: (2020)

Association of sleep duration in middle and old age with incidence of dementia
por: Sabia, Séverine, et al.
Publicado: (2021)

Alcohol consumption and risk of dementia: 23 year follow-up of Whitehall II cohort study
por: Sabia, Séverine, et al.
Publicado: (2018)

Timeline of pain before dementia diagnosis: a 27-year follow-up study
por: Kumaradev, Sushmithadev, et al.
Publicado: (2021)

Ten-Year Trends in Sales of Alzheimer Disease Drugs in France Compared With Sales in Germany, Spain, and the UK
por: Ben Hassen, Céline, et al.
Publicado: (2022)

Are ketogenic diets promising for Alzheimer’s disease? A translational review
por: Lilamand, Matthieu, et al.
Publicado: (2020)

Risk prediction models for dementia: role of age and cardiometabolic risk factors
por: Fayosse, Aurore, et al.
Publicado: (2020)

Sex differences and the role of education in cognitive ageing: analysis of two UK-based prospective cohort studies
por: Bloomberg, Mikaela, et al.
Publicado: (2021)

Contribution of smoking towards the association between socioeconomic position and dementia: 32-year follow-up of the Whitehall II prospective cohort study
por: Raggi, Martina, et al.
Publicado: (2022)

Blood-Based Kinase Assessments in Alzheimer’s Disease
por: Hugon, Jacques, et al.
Publicado: (2018)

Healthy behaviors at age 50 years and frailty at older ages in a 20-year follow-up of the UK Whitehall II cohort: A longitudinal study
por: Gil-Salcedo, Andres, et al.
Publicado: (2020)

Social inequalities in multimorbidity, frailty, disability, and transitions to mortality: a 24-year follow-up of the Whitehall II cohort study
por: Dugravot, Aline, et al.
Publicado: (2019)

The association of APOE ε4 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study
por: Gharbi-Meliani, Amin, et al.
Publicado: (2021)

Association of ideal cardiovascular health at age 50 with incidence of dementia: 25 year follow-up of Whitehall II cohort study
por: Sabia, Séverine, et al.
Publicado: (2019)

Comparison of the predictive accuracy of multiple definitions of cognitive impairment for incident dementia: a 20-year follow-up of the Whitehall II cohort study
por: Machado-Fragua, Marcos D, et al.
Publicado: (2021)

The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease
por: Öhrfelt, Annika, et al.
Publicado: (2016)

Trajectories of Unhealthy Behaviors in Midlife and Risk of Disability at Older Ages in the Whitehall II Cohort Study
por: Artaud, Fanny, et al.
Publicado: (2016)

Comparison of sex differences in cognitive function in older adults between high- and middle-income countries and the role of education: a population-based multicohort study
por: Bloomberg, Mikaela, et al.
Publicado: (2023)

New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer’s disease
por: Rose, Christiane, et al.
Publicado: (2012)

Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry
por: Camporesi, Elena, et al.
Publicado: (2022)

Full-length and C-terminal neurogranin in Alzheimer’s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays
por: Öhrfelt, Annika, et al.
Publicado: (2020)

Pro-Apoptotic Kinase Levels in Cerebrospinal Fluid as Potential Future Biomarkers in Alzheimer’s Disease
por: Paquet, Claire, et al.
Publicado: (2015)

Neurofilaments as Emerging Biomarkers of Neuroaxonal Damage to Differentiate Behavioral Frontotemporal Dementia from Primary Psychiatric Disorders: A Systematic Review
por: Davy, Vincent, et al.
Publicado: (2021)

Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study
por: Paquet, Claire, et al.
Publicado: (2016)

Detection of Outliers Due to Participants’ Non-Adherence to Protocol in a Longitudinal Study of Cognitive Decline
por: Dugravot, Aline, et al.
Publicado: (2015)

Association of sleep duration at age 50, 60, and 70 years with risk of multimorbidity in the UK: 25-year follow-up of the Whitehall II cohort study
por: Sabia, Séverine, et al.
Publicado: (2022)

Cerebrospinal Fluid PKR Level Predicts Cognitive Decline in Alzheimer’s Disease
por: Dumurgier, Julien, et al.
Publicado: (2013)

Clinical, socioeconomic, and behavioural factors at age 50 years and risk of cardiometabolic multimorbidity and mortality: A cohort study
por: Singh-Manoux, Archana, et al.
Publicado: (2018)

Sex differences in functional limitations and the role of socioeconomic factors: a multi-cohort analysis
por: Bloomberg, Mikaela, et al.
Publicado: (2021)

Obesity trajectories and risk of dementia: 28 years of follow-up in the Whitehall II Study
por: Singh-Manoux, Archana, et al.
Publicado: (2018)

Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study
por: Sabia, Séverine, et al.
Publicado: (2017)

Association of moderate and vigorous physical activity with incidence of type 2 diabetes and subsequent mortality: 27 year follow-up of the Whitehall II study
por: Yerramalla, Manasa S., et al.
Publicado: (2019)

The role of age, sex, and multimorbidity in 7-year change in prevalence of limitations in adults 60–94 years
por: Landré, Benjamin, et al.
Publicado: (2022)

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
por: Karikari, Thomas K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uf6s5umfrn2te2s1qmcio823qu